Our observed hub gene signature reversal in ovarian cancer cells, in tandem with the antitumor effects of KH‐4‐43, suggests that disruption of CRL4 activity is sufficient to impede some of the selective advantages employed by these cancerous cells. This evidence concerns the gene IL17RB and ovarian cancer.